Provided by Tiger Trade Technology Pte. Ltd.

Jaguar Animal Health

1.19
+0.02001.71%
Volume:246.43K
Turnover:303.66K
Market Cap:4.97M
PE:-0.03
High:1.30
Open:1.18
Low:1.15
Close:1.17
52wk High:33.25
52wk Low:1.00
Shares:4.18M
Float Shares:2.79M
Volume Ratio:1.64
T/O Rate:8.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-34.7371
EPS(LYR):-130.6878
ROE:-411.57%
ROA:-38.01%
PB:1.58
PE(LYR):-0.01

Loading ...

Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome

Reuters
·
Dec 15

Jaguar Health Issues Pre-Funded Warrants in Exchange for Preferred Stock

Reuters
·
Dec 13

Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation

Reuters
·
Dec 11

Jaguar Health Inc. Held Special Meeting of Stockholders

Reuters
·
Dec 09

Jaguar Health Seeks EMA Feedback on Canalevia EU Approval for Dog Diarrhea

Reuters
·
Dec 02

Jaguar Health Secures Australian Patent for Crofelemer in Treating Short Bowel Syndrome and Related Disorders

Reuters
·
Nov 24

Jaguar Health Submits Amended Protocol to FDA for Crofelemer MVID Trial

Reuters
·
Nov 20

Jaguar Health Extends $6.2 Million Note and Amends $36 Million Royalty Agreements with Investors

Reuters
·
Nov 20

Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows

Reuters
·
Nov 17

Jaguar Health Q3 EPS $(6.28) Misses $(5.08) Estimate, Sales $3.083M Miss $3.730M Estimate

Benzinga
·
Nov 17

Jaguar Health Q3 Basic EPS USD -6.28

THOMSON REUTERS
·
Nov 17

Jaguar Health Q3 Revenue USD 3.083 Million

THOMSON REUTERS
·
Nov 17

Jaguar Animal Health Secures $10.8M Note Agreement

TIPRANKS
·
Nov 15

Jaguar Health Secures $10.8 Million Secured Loan from Streeterville Capital

Reuters
·
Nov 15

Jaguar Health Inc. to Release Q3 2025 Financial Results

Reuters
·
Nov 14

Jaguar Health Inc expected to post a loss of $5.08 a share - Earnings Preview

Reuters
·
Nov 07

Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Trial

Reuters
·
Nov 06

Jaguar Health Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 29

Jaguar Health completes FDA Type C meeting on crofelemer trial

TIPRANKS
·
Oct 06

Jaguar Health Announces Promising Clinical Trial Results and Advances Regulatory Pathway for Crofelemer in Treating Rare Pediatric Disorder MVID

Reuters
·
Oct 06